Could Prozac treat autistic children?

After drinking mother’s milk spiked with the antidepressant Prozac for 19 days, infant mice bred to mimic the distinctive behaviors and brain abnormalities seen in autism experienced dramatic improvements in their social interactions, communication patterns and a wide range of neurochemical peculiarities that are a hallmark of the disorder, according to a new study.

And when newborn mice got a daily injection of Prozac in their first six days of life, the treatment appeared to restore normal vocalization patterns and reduce anxietylike behaviors well into adulthood, the new research showed.

The antidepressant Prozac, a selective-serotonin reuptake inhibitor (or SSRI), is one of the world’s most widely used medications. It is thought to elevate mood and quell anxiety by increasing the availability of the neurotransmitter serotonin in the spaces between certain types of brain cells.

Research on humans suggests that, during early brain development, those who will go on to develop autism have unusually low levels of serotonin in critical areas of the brain. The new study, published this week in the journal Science Advances, offers strong evidence that a serotonin shortage and faulty serotonin signaling play key roles in the neurodevelopmental disorder, in which social skills and verbal communication are impaired, behavior is often inflexible and sensory overload is common.

The study’s authors, from Hiroshima University and the RIKEN Brain Science Institute in Saitama, Japan, administered Prozac (also known by its generic name, fluoxetine) to the mice during the first three weeks of their lives. In a human child, the treatment period was roughly the equivalent of the span from 6 months of age to about 21⁄2 years.

At the University of California, Davis’ MIND Institute, the possibilities of SSRIs as an autism treatment are already under investigation in humans.

“This study supports what we see clinically,” said Dr. Randi J. Hagerman, medical director of the MIND Institute, which treats people with a range of neurodevelopmental disorders and conducts research on their causes and treatment.

In children between 2 and 6 years old with Fragile X, a genetic disorder that frequently causes autism, Hagerman and her colleagues have found that six months of treatment with the SSRI antidepressant sertraline (commercially marketed as Zoloft) improved the use of expressive language and other measures of cognitive function.